Is Contineum Therapeutics, Inc. (CTNM) a Buy, Sell, or Hold?
NASDAQ : CTNM
Contineum Therapeutics, Inc.
$14.23 USD
$0.22 (1.57%)
- Volume
- 132.76K
- Average Volume
- 309.68K
- Market Capitalization
- $532.01M
- P/E Ratio
- -7.30
- Dividend Yield
- 0.00%
- Price Target
- $16.00
- Year High
- $16.91
- Year Low
- $4.67
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $38.00
Insider Activity Summary (Last 12 Months)
Insiders Buying
31
Insiders Selling
46
Amount of Insider Selling
$201.02K
CTNM Insider Buying/Selling by Quarter
CTNM Insider Trading History
| Insider Name | Title | Date | Transaction | Cost | Filing Date |
|---|---|---|---|---|---|
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-07-08 | M-Exempt | 1.01 | 2026-07-10 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-07-09 | M-Exempt | 1.01 | 2026-07-10 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-07-09 | S-Sale | 16 | 2026-07-10 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-07-08 | M-Exempt | 1.01 | 2026-07-10 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-07-09 | M-Exempt | 1.01 | 2026-07-10 |
| Stengone Carmine N. | director, officer: CEO and President | 2026-07-08 | M-Exempt | 1.01 | 2026-07-08 |
| Stengone Carmine N. | director, officer: CEO and President | 2026-07-08 | M-Exempt | 1.01 | 2026-07-08 |
| Stengone Carmine N. | director, officer: CEO and President | 2026-07-08 | S-Sale | 16 | 2026-07-08 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-06-30 | M-Exempt | 1.01 | 2026-07-02 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-07-01 | M-Exempt | 1.01 | 2026-07-02 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-06-30 | S-Sale | 16.0372 | 2026-07-02 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-07-01 | S-Sale | 15.6667 | 2026-07-02 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-07-01 | S-Sale | 16.2369 | 2026-07-02 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-06-30 | M-Exempt | 1.01 | 2026-07-02 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-07-01 | M-Exempt | 1.01 | 2026-07-02 |
| Watkins Tim | officer: CMO & Head of Development | 2026-06-30 | M-Exempt | 4.5 | 2026-07-01 |
| Watkins Tim | officer: CMO & Head of Development | 2026-06-30 | M-Exempt | 4.5 | 2026-07-01 |
| Watkins Tim | officer: CMO & Head of Development | 2026-06-30 | S-Sale | 16.0242 | 2026-07-01 |
| Stengone Carmine N. | director, officer: CEO and President | 2026-06-30 | M-Exempt | 1.01 | 2026-07-01 |
| Stengone Carmine N. | director, officer: CEO and President | 2026-06-30 | M-Exempt | 1.26 | 2026-07-01 |
| Stengone Carmine N. | director, officer: CEO and President | 2026-06-30 | M-Exempt | 1.26 | 2026-07-01 |
| Stengone Carmine N. | director, officer: CEO and President | 2026-06-30 | M-Exempt | 1.01 | 2026-07-01 |
| Stengone Carmine N. | director, officer: CEO and President | 2026-06-30 | S-Sale | 16.008 | 2026-07-01 |
| Miralles Gines Diego | director | 2026-06-26 | A-Award | 14.19 | 2026-06-26 |
| Lyons-Williams Lori | director | 2026-06-26 | A-Award | 14.19 | 2026-06-26 |
| Ware Olivia C | director | 2026-06-26 | A-Award | 14.19 | 2026-06-26 |
| Schimmelpennink Evert B. | director | 2026-06-26 | A-Award | 14.19 | 2026-06-26 |
| Ignelzi Troy A. | director | 2026-06-26 | A-Award | 14.19 | 2026-06-26 |
| Brady Todd R. | director | 2026-06-26 | A-Award | 14.19 | 2026-06-26 |
| Boyce Sarah | director | 2026-06-26 | A-Award | 14.19 | 2026-06-26 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-06-01 | S-Sale | 13.1564 | 2026-06-01 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-05-01 | S-Sale | 13.06 | 2026-05-01 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-05-01 | S-Sale | 13.84 | 2026-05-01 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-04-06 | S-Sale | 13.4326 | 2026-04-06 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-03-02 | S-Sale | 15.0084 | 2026-03-02 |
| Watkins Tim | officer: CMO & Head of Development | 2026-03-02 | M-Exempt | 4.5 | 2026-03-02 |
| Watkins Tim | officer: CMO & Head of Development | 2026-03-02 | M-Exempt | 4.5 | 2026-03-02 |
| Watkins Tim | officer: CMO & Head of Development | 2026-03-02 | S-Sale | 15.0153 | 2026-03-02 |
| Stengone Carmine N. | director, officer: CEO and President | 2026-02-24 | M-Exempt | 1.26 | 2026-02-26 |
| Stengone Carmine N. | director, officer: CEO and President | 2026-02-25 | M-Exempt | 1.26 | 2026-02-26 |
| Stengone Carmine N. | director, officer: CEO and President | 2026-02-24 | M-Exempt | 1.26 | 2026-02-26 |
| Stengone Carmine N. | director, officer: CEO and President | 2026-02-25 | M-Exempt | 1.26 | 2026-02-26 |
| Stengone Carmine N. | director, officer: CEO and President | 2026-02-24 | S-Sale | 16.0195 | 2026-02-26 |
| Stengone Carmine N. | director, officer: CEO and President | 2026-02-25 | S-Sale | 16.0155 | 2026-02-26 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-02-24 | M-Exempt | 1.01 | 2026-02-26 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-02-25 | M-Exempt | 1.01 | 2026-02-26 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-02-24 | S-Sale | 16.0316 | 2026-02-26 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-02-25 | S-Sale | 16.0115 | 2026-02-26 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-02-24 | M-Exempt | 1.01 | 2026-02-26 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-02-25 | M-Exempt | 1.01 | 2026-02-26 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-02-19 | M-Exempt | 1.01 | 2026-02-20 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-02-19 | S-Sale | 16 | 2026-02-20 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-02-19 | M-Exempt | 1.01 | 2026-02-20 |
| Stengone Carmine N. | director, officer: CEO and President | 2026-02-11 | M-Exempt | 1.26 | 2026-02-13 |
| Stengone Carmine N. | director, officer: CEO and President | 2026-02-11 | M-Exempt | 1.26 | 2026-02-13 |
| Stengone Carmine N. | director, officer: CEO and President | 2026-02-11 | S-Sale | 16 | 2026-02-13 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-02-11 | M-Exempt | 1.01 | 2026-02-13 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-02-11 | S-Sale | 16 | 2026-02-13 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-02-11 | M-Exempt | 1.01 | 2026-02-13 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-02-03 | S-Sale | 14.8229 | 2026-02-05 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-02-03 | S-Sale | 15.2451 | 2026-02-05 |
| Healy John Stephen | officer: General Counsel and Corp Sec | 2026-01-30 | A-Award | 14.26 | 2026-01-30 |
| Slover Peter T | officer: Chief Financial Officer | 2026-01-30 | A-Award | 14.26 | 2026-01-30 |
| Stengone Carmine N. | director, officer: CEO and President | 2026-01-30 | A-Award | 14.26 | 2026-01-30 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-01-30 | A-Award | 14.26 | 2026-01-30 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-01-30 | A-Award | 14.26 | 2026-01-30 |
| Watkins Tim | officer: CMO & Head of Development | 2026-01-28 | M-Exempt | 4.5 | 2026-01-30 |
| Watkins Tim | officer: CMO & Head of Development | 2026-01-30 | A-Award | 14.26 | 2026-01-30 |
| Watkins Tim | officer: CMO & Head of Development | 2026-01-28 | M-Exempt | 4.5 | 2026-01-30 |
| Watkins Tim | officer: CMO & Head of Development | 2026-01-28 | S-Sale | 14.0861 | 2026-01-30 |
| Watkins Tim | officer: CMO & Head of Development | 2026-01-28 | S-Sale | 14.4848 | 2026-01-30 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-01-05 | S-Sale | 10.3483 | 2026-01-06 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2026-01-05 | S-Sale | 11.1298 | 2026-01-06 |
| Watkins Tim | officer: CMO & Head of Development | 2025-12-29 | M-Exempt | 4.5 | 2025-12-30 |
| Watkins Tim | officer: CMO & Head of Development | 2025-12-29 | M-Exempt | 4.5 | 2025-12-30 |
| Watkins Tim | officer: CMO & Head of Development | 2025-12-29 | S-Sale | 12.0627 | 2025-12-30 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2025-12-23 | S-Sale | 12.2324 | 2025-12-30 |
| Boyce Sarah | director | 2025-06-26 | A-Award | 4.01 | 2025-06-26 |
| Schimmelpennink Evert B. | director | 2025-06-26 | A-Award | 4.01 | 2025-06-26 |
| Brady Todd R. | director | 2025-06-26 | A-Award | 4.01 | 2025-06-26 |
| Ignelzi Troy A. | director | 2025-06-26 | A-Award | 4.01 | 2025-06-26 |
| Lyons-Williams Lori | director | 2025-06-26 | A-Award | 4.01 | 2025-06-26 |
| Ware Olivia C | director | 2025-06-26 | A-Award | 4.01 | 2025-06-26 |
| Miralles Gines Diego | director | 2025-06-26 | A-Award | 4.01 | 2025-06-26 |
| Watkins Tim | officer: CMO & Head of Development | 2025-04-28 | A-Award | 4.5 | 2025-04-28 |
| Watkins Tim | officer: CMO & Head of Development | 2025-04-28 | A-Award | 4.5 | 2025-04-28 |
| Watkins Tim | officer | 2025-04-28 | 0 | 2025-04-28 | |
| Miralles Gines Diego | director | 2025-03-14 | A-Award | 6.67 | 2025-03-17 |
| Miralles Gines Diego | director | 2025-03-14 | 17.92 | 2025-03-17 | |
| Healy John Stephen | officer: General Counsel and Corp Sec | 2025-01-31 | A-Award | 9.79 | 2025-01-31 |
| Slover Peter T | officer: Chief Financial Officer | 2025-01-31 | A-Award | 9.79 | 2025-01-31 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2025-01-31 | A-Award | 9.79 | 2025-01-31 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2025-01-31 | A-Award | 9.79 | 2025-01-31 |
| Huhn Stephen L. | officer: CMO & Sr VP, Clinical Dev. | 2025-01-31 | A-Award | 9.79 | 2025-01-31 |
| Stengone Carmine N. | director, officer: CEO and President | 2025-01-31 | A-Award | 9.79 | 2025-01-31 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2024-11-25 | S-Sale | 16.0172 | 2024-11-27 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2024-11-18 | S-Sale | 16.3738 | 2024-11-20 |
| Lorrain Daniel S. | officer: Chief Scientific Officer | 2024-11-18 | S-Sale | 17.05 | 2024-11-20 |
| JOHNSON & JOHNSON | 10 percent owner | 2024-04-09 | 0 | 2024-04-10 |